A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

NCT07359859 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: Cyclophosphamide
DRUG: Cyclophosphamide
DRUG: Mycophenolate Mofetil
DRUG: Ruxolitinib
DRUG: Tacrolimus
DRUG: Tacrolimus

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]